Black Diamond Therapeutics, Inc. — Director's Dealing 2021

Apr 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Black Diamond Therapeutics, Inc. (BDTX)
CIK: 0001701541
Period of Report: 2021-04-05

Reporting Person: Roberts Christopher D. (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-05	Common Stock	M	2500	$10.86	Acquired	5700	Direct
2021-04-05	Common Stock	S	2500	$25.539	Disposed	3200	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-05	Stock Option (Right to Buy)	$10.86	M	2500	Disposed	2029-09-08	Common Stock (2500)	Direct

Footnotes

F1: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.165 to $26.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: 25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter.